William B. Pearse, MD

home / authors / william-b-pearse-md

Articles

William B. Pearse, MD

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

William B. Pearse, MD
April 18th 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Read More

William B. Pearse, MD

Dr Pearse on the Utility of Pirtobrutinib in Relapsed/Refractory MCL

William B. Pearse, MD
April 16th 2024

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Read More

William B. Pearse, MD

Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL

William B. Pearse, MD
February 19th 2024

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

Read More

William B. Pearse, MD

Dr Pearse on Efforts to Elucidate the Optimal Sequencing of BTK Inhibitors in MCL

William B. Pearse, MD
February 8th 2024

William B. Pearse, MD, discusses unanswered questions regarding the sequencing of pirtobrutinib and other BTK inhibitors in mantle cell lymphoma.

Read More

William B. Pearse, MD

Dr Pearse on the Use of BTK Inhibitors in Relapsed/Refractory MCL

William B. Pearse, MD
January 25th 2024

William B. Pearse, MD, discusses the current and future roles of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data